secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001193125-26-094967
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences reports $336M cash; JADE101 Phase 1 data expected Q2 2026
--------------------------------------------------------------------------

- Cash, equivalents, and investments of $336.2M as of Dec 31, 2025; runway into first half 2028.
- Q4 2025 net loss $31.9M vs $30.1M Q4 2024; full year net loss $127.4M.
- JADE101 Phase 1 interim data expected Q2 2026; Phase 2 IgA nephropathy trial to start mid-2026.
- JADE201 (anti-BAFF-R) Phase 1 in rheumatoid arthritis expected Q2 2026; interim data 2027.
- Raised ~$180M in Q4 2025 private placements from new and existing investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526094967/0001193125-26-094967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526094967/d69373d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-094967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer